Lung mechanics in congenital heart disease with increased and decreased pulmonary blood flow

1977 ◽  
Vol 90 (2) ◽  
pp. 192-195 ◽  
Author(s):  
E. Bancalari ◽  
M.J. Jesse ◽  
H. Gelband ◽  
O. Garcia
2021 ◽  
Vol 12 (2) ◽  
pp. 213-219
Author(s):  
R. Allen Ligon ◽  
Larry A. Latson ◽  
Mark M. Ruzmetov ◽  
Kak-Chen Chan ◽  
Immanuel I. Turner ◽  
...  

Background: Surgical pulmonary artery banding (PAB) has been limited in practice because of later requirement for surgical removal or adjustment. The aim of this study is to describe our experience creating a dilatable PAB via transcatheter balloon dilation (TCBD) in congenital heart disease (CHD) patients. Methods: Retrospective chart review of adjustable PAB—outline anatomical variants palliated and patient outcomes. Results: Sixteen patients underwent dilatable PAB—median age 52 days (range 4-215) and weight 3.12 kg (1.65-5.8). Seven (44%) of the patients were premature, 11 (69%) had ventricular septal defect(s) with pulmonary over-circulation, four (25%) atrioventricular septal defects, and four (25%) single ventricle physiology. Subsequent to the index procedure: five patients have undergone intracardiac complete repair, six patients remain well palliated with no additional intervention, and four single ventricles await their next palliation. One patient died from necrotizing enterocolitis (unrelated to PAB) and one patient required a pericardiocentesis postoperatively. Five patients underwent TCBD of the PAB without complication—Two had one TCBD, two had two TCBD, and another had three TCBD. The median change in saturation was 14% (complete range 6-22) and PAB diameter 1.7 mm (complete range 1.1-5.2). Median time from PAB to most recent outpatient follow-up was 868 days (interquartile range 190-1,079). Conclusions: Our institution has standardized a PAB technique that allows for transcatheter incremental increases in pulmonary blood flow over time. This methodology has proven safe and effective enough to supplant other institutional techniques of limiting pulmonary blood flow in most patients—allowing for interval growth or even serving as the definitive palliation.


PEDIATRICS ◽  
1978 ◽  
Vol 61 (4) ◽  
pp. 534-536
Author(s):  
Alan B. Lewis ◽  
Paul R. Lurie

A small-for-gestational-age premature infant with severe tetralogy of Fallot was treated with prostaglandin E1 to dialate the ductus arteriosus and increase pulmonary blood flow. The infusion was continued for 29 days without complication at which time surgery was performed.


2020 ◽  
Vol 73 (10) ◽  
pp. 859-861
Author(s):  
Laura Marfil-Godoy ◽  
Gerard Martí-Aguasca ◽  
Queralt Ferrer-Menduiña ◽  
Gemma Giralt-García ◽  
Pedro Betrián-Blasco

Circulation ◽  
1969 ◽  
Vol 40 (6) ◽  
pp. 777-784 ◽  
Author(s):  
IRWIN B. BORUCHOW ◽  
THOMAS D. BARTLEY ◽  
LARRY P. ELLIOTT ◽  
MYRON W. WHEAT ◽  
L. JEROME KROVETZ ◽  
...  

2011 ◽  
Vol 6 (03) ◽  
pp. 193-196
Author(s):  
Koichiro Niwa ◽  
Mika Uchishiba ◽  
Hiroyuki Aotsuka ◽  
Shigeru Tateno ◽  
Kimimasa Tobita ◽  
...  

2003 ◽  
Vol 284 (2) ◽  
pp. H480-H490 ◽  
Author(s):  
Boaz Ovadia ◽  
Olaf Reinhartz ◽  
Robert Fitzgerald ◽  
Janine M. Bekker ◽  
Michael J. Johengen ◽  
...  

Altered pulmonary vascular reactivity is a source of morbidity and mortality for children with congenital heart disease and increased pulmonary blood flow. Nitric oxide (NO) and endothelin (ET)-1 are important mediators of pulmonary vascular reactivity. We hypothesize that early alterations in endothelial function contribute to the altered vascular reactivity associated with congenital heart disease. The objective of this study was to characterize endothelial function in our lamb model of increased pulmonary blood flow at 1 wk of life. Eleven fetal lambs underwent in utero placement of an aortopulmonary vascular graft (shunt) and were studied 7 days after delivery. The pulmonary vasodilator response to both intravenous ACh (endothelium dependent) and inhaled NO (endothelium independent) was similar in shunted and control lambs. In addition, tissue NOx, NO synthase (NOS) activity, and endothelial NOS protein levels were similar. Conversely, the vasodilator response to both ET-1 and 4Ala-ET-1 (an ETBreceptor agonist) were attenuated in shunted lambs, and tissue ET-1 concentrations were increased ( P < 0.05). Associated with these changes were an increase in ET-converting enzyme-1 protein and a decrease in ETBreceptor protein levels ( P < 0.05). These data demonstrate that increased pulmonary blood flow induces alterations in ET-1 signaling before NO signaling and suggest an early role for ET-1 in the altered vascular reactivity associated with increased pulmonary blood flow.


1999 ◽  
Vol 9 (2) ◽  
pp. 141-149 ◽  
Author(s):  
Henrik Holmström ◽  
Christian Hall ◽  
Oddvar Stokke ◽  
Harald Lindberg ◽  
Erik Thaulow

AbstractWe postulated previously that variables related to pulmonary flow are independent predictors of levels of atrial natriuretic peptide in children with congenital heart disease. The aim of this study was to test this hypothesis in relation to other hemodynamic and clinical variables.During catheterization we measured the levels of plasma N-terminal atrial natriuretic peptide prohormone in the plasma of 68 children with congenital heart disease. All had undergone complete clinical, echocardiographic and invasive hemodynamic investigations. The influence on the prohormone was analyzed for 10 different variables in a multiple linear regression model. The variability could be explained in large parts (adjusted R2 = 77.2%) by variations in atrial pressures or sizes, together with the degree of excessive pulmonary blood flow and signs of heart failure.A value for atrial natriuretic peptide prohormone above 800 pmol/1 predicted hemodynamic imbalance (defined as elevated pressures in left or right atrium or the pulmonary arteries, and/or Qp/Qs > 1.5) with a specificity of 94%, a sensitivity of 73%, a positive likelihood ratio of 12.2, and a negative likelihood ratio of 0.29.In conclusion, variables related to pulmonary blood flow are influential determinants of the levels of atrial natriureic peptide in children with congenital heart disease. Atrial pressures, and symptoms of heart failure are also of major importance.


Sign in / Sign up

Export Citation Format

Share Document